Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study

Slični predmeti

• Baricitinib versus placebo or adalimumab in rheumatoid arthritis
  od: Taylor, P, i dr.
  Izdano: (2017)
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
  od: Keystone, E, i dr.
  Izdano: (2015)
• Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
  od: Taylor, P, i dr.
  Izdano: (2017)
• Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
  od: Taylor, P, i dr.
  Izdano: (2016)
• Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
  od: Taylor, P, i dr.
  Izdano: (2019)